Argeris N Karabelas

CIK 1191229 · last filed 2026-06-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.28M

Companies

Total Filings

Lifetime Open-Market Net

-$32.53M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

VNDA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Related Filers

Jan Leschly — 13 joint filings, latest 2009-07-23

David Russ Ramsay — 13 joint filings, latest 2009-07-23

Bausch Health Companies Inc. — 10 joint filings, latest 2022-06-28

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
RGNX	Director	28,861	$8.14	$234.9K	-$631.3K	18	2026-06-02
BHC	Director	123,715	$8.47	$1.05M	$0	4	2022-06-28
ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted	Director	402,437	—	—	$3.62M	2	2015-06-26
HUMAN GENOME SCIENCES INC (HGSI) Delisted	Director	0	—	—	$0	13	2012-08-01
VNDA	Director	0	$4.09	$0	-$35.52M	13	2011-06-17
NITROMED INC (NTMD) Delisted	Director	—	—	—	$0	2	2008-05-16

Recent Filings · Page 3 of 7

61 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2018-05-08	—	Grant (A)	+13,881	$0
2018-05-04	—	Grant (A)	+14,285	$0
2017-05-26	RGNX	Grant (A)	—	$0	EDGAR
2017-05-05	—	Grant (A)	+25,406	$0
2016-08-12	—	Buy (P)	+4,000	$98.6K
2016-06-21	—	Grant (A)	+16,726	$0
2016-06-02	RGNX	Grant (A)	—	$0	EDGAR
2015-09-22	RGNX	Grant (A)	—	$0	EDGAR
2015-09-17	RGNX	Grant (A)	—	$0	EDGAR
2015-06-26	ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted	Grant (A)	—	$0	EDGAR

Showing 21–30 of 61

Prev Page 3 of 7 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.